علاج التهاب الفقار اللاصق مع التهاب المفاصل المحيطية

References

DOI: 10.1136/ard-2022-223296

• Patients with purely axial disease should normally not be treated with csDMARDs; sulfasalazine may be considered in patients with peripheral arthritis.
• In patients with predominantly peripheral manifestations, following recommendations 7 and 8, failure to treatment includes one glucocorticoid injection, if appropriate, and the use of sulfasalazine.
• TNFi, IL-17i or JAKi should be considered in patients with persistently high disease activity despite conventional treatments (figure 1); current practice is to start a TNFi or IL-17i.
• Figure 3 summarises the criteria for continuation, namely that after at least 12 weeks of treatment, the disease activity has substantially decreased, as assessed by the ASDAS clinical important improvement, that is, improvement in ASDAS ≥1.1, together with the positive opinion from the rheumatologist to continue.